Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;37(18):3725-3733.
doi: 10.1038/s41433-023-02610-z. Epub 2023 Jun 7.

Tyrosine Kinase Inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema

Shruti Chandra #  1   2 , Emanuel Yuquan Tan #  1   3 , Theo Empeslidis  4 , Sobha Sivaprasad  5   6
Affiliations
Review

Tyrosine Kinase Inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema

Shruti Chandra et al. Eye (Lond). 2023 Dec.

Abstract
in English, Chinese

The advent of intravitreal anti-VEGF injections has revolutionised the treatment of both neovascular age-related macular degeneration (nAMD or wet AMD) and diabetic macular oedema (DMO). Despite their efficacy, anti-VEGF injections precipitate significant treatment burden for patients, caregivers and healthcare systems due to the high frequency of injections required to sustain treatment benefit. Therefore, there remains an unmet need for lower-burden therapies. Tyrosine kinase inhibitors (TKI) are a novel class of drugs that may have considerable potential in addressing this issue. This review will summarise and discuss the results of various pilot studies and clinical trials exploring the role of TKIs in treatment of nAMD and DMO, highlighting promising candidates and possible challenges in developments.

摘要: 玻璃体内注射抗VEGF药物的出现改变了新生血管性年龄相关性黄斑变性 (nAMD或湿性AMD) 和糖尿病性黄斑水肿 (DMO) 的治疗。尽管抗VEGF治疗有效, 但由于维持治疗效果需要高频次注射, 给患者、护理人员和医保系统带来了巨大的治疗负担。因此, 对低负担治疗的需求仍未得到满足。酪氨酸激酶抑制剂 (TKI)为一种新型药物, 在解决这一问题方面可能具有很大的潜力。本综述将总结和讨论TKI在nAMD和DMO治疗中作用的各种探索性研究和临床试验的结果, 强调有前景的备选药物和开发中可能面临的挑战。.

PubMed Disclaimer

Conflict of interest statement

S.S. has received funding/fees from Bayer, Novartis, Abbvie, Roche, Boehringer Ingelheim, Optos, EyeBiotech, Biogen, and Apellis. T.E. is an employee of Boehringer Ingelheim Ltd, Germany. S.S. and S.C. are members of the Eye editorial board.

Figures

Fig. 1
Fig. 1. Schematic representation of tyrosine kinase inhibitors (TKIs) and the receptors they target.
Ang 2- Angiopoietin 2; Flt- fms like tyrosine kinase; KDR-Kinase insert domain receptor;PDGF-Platelet derived growth factor; PDGFR- Platelet derived growth factor receptor; PIGF- Placenta growth factor;VEGF- Vascular endothelial growth factor; VEGFR- Vascular endothelial growth factor receptor.
See this image and copyright information in PMC

References

    1. Khan M, Aziz AA, Shafi NA, Abbas T, Kha mab. Cells NLM (Medlin) 2020;9:1869. doi: 10.3390/cells9081869. - DOI - PMC - PubMed
    1. Lorenzo-Soler L, Praphanwittaya P, Olafsdottir OB, Kristinsdottir IM, Asgrimsdottir GM, Loftsson T, et al. Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye. Acta Ophthalmol. 2022;100:788–96. doi: 10.1111/aos.15101. - DOI - PubMed
    1. Mirando AC, Shen J, Silva RLE, Chu Z, Sass NC, Lorenc VE, et al. A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling. JCI Insight. 2019;4:e122043. doi: 10.1172/jci.insight.122043. - DOI - PMC - PubMed
    1. Witmer AN, Vrensen GFJM, van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retinal Eye Res. 2003;22:1–29. doi: 10.1016/S1350-9462(02)00043-5. - DOI - PubMed
    1. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Vol. 86, Cancer Treatment Reviews. W.B. Saunders Ltd; 2020. - PubMed

MeSH terms

Substances

LinkOut - more resources